jcp conference-coverage

Conference Coverage

Incidence and Survival Outcomes of Diffuse Large B-Cell Lymphoma in Adolescents and Young Adults

12/07/2023

A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.

A team of researchers conducted...

12/07/2023

Journal of Clinical Pathways

Conference Coverage

The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration

12/06/2023

Grace Taylor , MS, MA;

Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...

Using data from a real-world...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Impact of Implementing Universal Germline Genetic Testing for Breast Cancer in Rural Communities

12/06/2023

Brandon Twyford ;

New research underscores the high implementation rate and significant impact of universal germline genetic testing (GGT) for breast cancer (BC) in rural medical practices on shared treatment decision-making.

New research underscores the...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Adverse Event-Related Health Care Utilization and Cost Among Patients with HR+/HER2- Metastatic Breast Cancer

12/06/2023

Brandon Twyford ;

Research presented at SABCS 2023 examines the economic impact of treating HR+/HER2- metastatic breast cancer, revealing that costs related to adverse events in patients undergoing late-line chemotherapy treatments are significant and...

Research presented at SABCS 2023...

12/06/2023

Journal of Clinical Pathways

News

Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis

12/06/2023

Grace Taylor , MS, MA;

Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...

Aditya Bardia, MD, and...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Study Reveals Insights into Cost-Effectiveness of Multigene Assays in Early-Stage Breast Cancer Treatment

12/06/2023

Brandon Twyford ;

A recent study presented at the 2023 ASH Annual Meeting & Exposition compared the cost-effectiveness of four multigene assays used in early-stage breast cancer treatment, and revealed which was the most beneficial for cost savings and...

A recent study presented at the...

12/06/2023

Journal of Clinical Pathways

Videos

Players and Disruptors in Health Care Industry Consolidation

12/05/2023

Ronald Barkley , MS, JD;

Ronald Barkley, MS, JD, Cancer Center Business Development Group, provides an overview of the current consolidation of the health care industry and the major players and disruptors leading this transformation.

Ronald Barkley, MS, JD, Cancer...

12/05/2023

Cancer Care Business Exchange

News

Disparities in Palliative Care Access Highlighted in Nationwide Study of Deceased Lymphoma Patients

12/04/2023

Brandon Twyford ;

Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...

Nationwide study reveals that...

12/04/2023

Journal of Clinical Pathways

News

Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

12/04/2023

Emry Lloyd ;

Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.

Jennifer Brown, MD, and...

12/04/2023

Journal of Clinical Pathways

News

Evaluation of First-Line Treatment Outcomes in Elderly Patients with Diffuse Large B-Cell Lymphoma

12/04/2023

Grace Taylor , MS, MA;

Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.

Steven Bair, MD, and colleagues...

12/04/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products